A comparative evaluation of Eosin‐5′‐maleimide flow cytometry reveals a high diagnostic efficacy for hereditary spherocytosis. (24th June 2016)

• Record Type: Journal Article
• Authors: Joshi, P.; Aggarwal, A.; Jamwal, M.; Sachdeva, M. U. S.; Bansal, D.; Malhotra, P.; Sharma, P.; Das, R.
• Is Part Of: International journal of laboratory hematology. Volume 38:Number 5(2016:Oct.)
• Page Start: 520
• Page End: 526
• Publication Date: 2016-06-24
• Subjects: Eosin‐5′‐maleimide -- flow cytometer -- hereditary spherocytosis -- North India; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Hematology -- Periodicals; 616.15005
• DOI: 10.1111/ijlh.12533
• Languages: English
• ISSNs: 1751-5521

Abstract

Summary: Introduction: Laboratory diagnosis of hereditary spherocytosis (HS) relies on increased incubated red cell osmotic fragility test for screening. We evaluated the diagnostic role of eosin‐5′‐maleimide (EMA) binding test by flow cytometry in spherocytic and microcytic hypochromic hematological disorders in North Indians. Methods: EMA binding test using flow cytometry was performed on 55 HS (40 families), 26 iron deficiency anemia (IDA), 32 β‐thalassemia trait (βTT), and 10 autoimmune hemolytic anemia (AIHA) cases and 121 normals. Mean channel fluorescence (MCF) and coefficient of variation (CV) were studied. Different MCF parameters (MCF, MCF ratio, percent decrease MCF) and percent increase in CV were analyzed. Receiver operating characteristics analysis was performed to determine best cutoff values, sensitivity, and specificity for discriminating HS from other red cell disorders. Results: MCF ratio of HS group was significantly lower than normals (0.67 ± 0.07 vs . 1.01 ± 0.05, P < 0.001) and other cases. All patients with HS showed MCF ratio to be ≤0.79. Four postsplenectomy cases with near‐normal hemograms also revealed low MCF ratio, showing the specificity of the test. Conclusions: EMA assay was efficient to diagnose cases of HS including postsplenectomy cases and shows no overlap with IDA, βTT, and AIHA.